PACS, RIS, and CVIS – Market Insights – United States

The COVID-19 global pandemic has had a negative impact on the US PACS, RIS, and CVIS market, resulting in declines in unit sales and revenue in 2020. However, following a period of recovery, the market will grow modestly through 2031, driven by the increasing movement toward value-based healthcare and effective population health management in the US, as well as continued hospital consolidation, although market saturation, healthcare system budgetary constraints, and competition from enterprise solutions will limit the pace of market expansion.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for PACS, RIS, and CVIS in the US from 2019 through 2031.

The COVID-19 pandemic has negatively impacted the US PACS, RIS, and CVIS market.

How strongly has the PACS, RIS, and CVIS market been impacted?

At what pace are the PACS, RIS, and CVIS markets expected to recover?

The US market for PACS, RIS, and CVIS is nearing saturation across many facility types.

What is the penetration of PACS, RIS, and CVIS in the US across different facility types?

What is the expected volume of replacement sales through 2031?

Vendors of PACS, RIS, and CVIS must develop new competitive strategies to address the evolving purchasing priorities and needs of healthcare facilities.

How will mergers and acquisitions change the competitive landscape of the PACS, RIS, and CVIS market?

How will hospital consolidation and declining physician influence affect purchasing decisions for PACS, RIS, and CVIS? Which vendors will benefit the most from this changing landscape?

How can traditional PACS vendors position themselves in a market that increasingly prioritizes vendor neutrality and interoperability between IT solutions?

How will AI integration affect the competitiveness of certain companies?

Cybersecurity in the HCIT sector is a growing topic of discussion, and vendors are increasingly investing in improving the security of their systems.

How has hospital consolidation affected cybersecurity needs in this space?

How and why are cybersecurity-related certifications being used by PACS, RIS, and CVIS competitors?

Adoption of new emerging technologies as replacements for traditional PACS, RIS, and CVIS will rapidly change market prospects.

What are the emerging technologies that are affecting the future of the traditional PACS, RIS, and CVIS markets?

How will the adoption of enhanced diagnostic tools such as AI and machine learning change the market, and what are the competitive implications of this technology?

How will widespread adoption of EHRs and VNAs affect the PACS, RIS, and CVIS markets?

Table of contents

PACS, RIS, and CVIS - Market Insights - United States

Sumit Jain, MS Pharm

Sumit Jain is a senior team lead within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Clarivate, focusing on diagnostic imaging capital equipment and healthcare IT markets. Sumit holds a Bachelor’s degree in Pharmacy from the Rajiv Gandhi Technical University, Bhopal, and a Master’s degree in Pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Mohali.

Contact sales Login to access report

Back to all Medtech Insights reports